Comparative Efficacy and Tolerability of Quetiapine and Clozapine in Treatment Resistant Schizophrenia (TRS)

Mitesh Kumar0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Patients suffering from schizophrenia as per ICD 10 (Diagnostic Criteria for Research ) criteria and fulfilling modified version of Conley and Kellyâ??s criteria of Treatment Resistant Schizophrenia(TRS) which is defined as:
•a) No clinical response with two different antipsychotics used separately in the dose range of 400â??600 mg of chlorpromazine per day or equivalents for 6 weeks,
•b) no period of good social or occupational functioning at least in last one year, plus a minimum Clinical Global Impressions (CGI) Scale rating of 4 (moderately ill),
•c)BPRS total score > 45, and a score of >4 on 2 of 4 positive items.
•2) Patients who are accompanied by reliable informants.
•3) Patients and relatives willing to give informed consent

•1) Patients of co-morbid substance dependence except nicotine use.
•2) Patients who have received clozapine or quetiapine in the past.
•3) Patients with sub normal intelligence.
•4) Patient with heart conduction defects, history of agranulocytosis or TLC less than 3500 per mm3
•and pre-existing diabetes mellitus, hypertension.
•5) Patient with neurological disorders such as head injury, epilepsy, movement disorder and tumours.
•6) Pregnant and lactating mother.
•7) Patient with late onset schizophrenia ( after 45 years ).

发起方

Mitesh Kumar